NextCure Inc NXTC.OQ NXTC.O is expected to show no change in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for NextCure Inc is for a loss of $3.98 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for NextCure Inc is $17.50, about 28% above its last closing price of $12.60
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -4.61 | -4.61 | -11.29 | Missed | -144.6 |
Mar. 31 2025 | -4.85 | -4.80 | -4.68 | Beat | 2.5 |
Dec. 31 2024 | -3.90 | -4.02 | -4.92 | Missed | -22.4 |
Sep. 30 2024 | -4.44 | -4.14 | -4.92 | Missed | -18.8 |
Jun. 30 2024 | -4.55 | -4.52 | -6.60 | Missed | -46 |
Mar. 31 2024 | -5.57 | -5.52 | -7.32 | Missed | -32.5 |
Dec. 31 2023 | -5.76 | -6.50 | -6.24 | Beat | 4 |
Sep. 30 2023 | -7.93 | -7.89 | -6.12 | Beat | 22.4 |
This summary was machine generated November 3 at 11:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)